BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Short-term Debt · Q1 FY2026 · quarter ended Mar 2026
Short-term debt remains negative
Q1 FY2026 short-term debt was $538K, compared with $0 a year earlier.
Context
- Short-term debt amounted to 0.1% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
- Short-term debt increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 70.1K | +62.6% |
| FY2022 | 2022-12-31 | 43.11K | +16.6% |
| FY2021 | 2021-12-31 | 36.96K | — |
Short-term Debt vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term debt is compared through growth and share of total assets rather than absolute size.
- Short-term debt amounts to 0.1% of total assets for BBOT, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $3.06M USD | — | — | 0.3% | |
SEPNSepterna, Inc. | Sep 2026 | $2.51M USD | — | — | 0.4% |
| Mar 2026 | $2.12M USD | — | — | 0.6% | |
| Mar 2026 | $1.92M USD | — | — | 0.8% | |
| Mar 2026 | $667K USD | -96.1% | — | 0.2% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $538K USD | — | — | 0.1% |
| Mar 2026 | CHF 414.76K CHF | — | — | 0.2% | |
| Sep 2026 | $0 USD | — | +6.7% | 0.0% | |
| Jun 2026 | $0 USD | — | — | 0.0% | |
| Aug 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding BBOT) | — | -96.1% | +6.7% | 0.2% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.